Key facts
- Notable investors include Huaou Equity Investment, Jinqiao Capital.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Caihe Biology
- ·The full record, as it builds
Funding rounds
No funding rounds for Caihe Biology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Caihe Biology
Developer of chemical-based pharmaceutical ingredients intended for therapeutic and nutritional applications. The company offers synthesis of active compounds, formulation of advanced intermediates, and production of food-grade additives using proprietary lab-scale and pilot-scale technologies, serving pharmaceutical and nutraceutical manufacturers to access high-purity materials, improve formulation efficiency, meet international quality standards, and support environmentally conscious production processes.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2019
- Employees
- 3
- Website
- caihepharm.com/
- Ownership
- Privately Held (backing)
Caihe Biology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Caihe Biology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Caihe Biology in its N-PORT filings yet. We sweep new filings monthly.